GlobeNewswire Inc. · Mar 1, 2022
Recro Reports Fourth Quarter and Year End 2021 Financial Results
Recorded Q4 Revenue of $22.3 Million; Full Year Revenue of $75.4 Million
RE
NASDAQ · REPH
Recro Pharma, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$2.09
Down-$0.01 (-0.48%)
Updated Sep 19, 2026, 5:02 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 177.42M
- P/E ratio
- -7.89
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 137.54K
- Avg. volume
- 128.49K
Price performance
REPH price history
1M range · 0 trading sessions · Daily adjusted prices
REPH does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest REPH news
The latest Smart Investors Daily articles mentioning REPH.
Stock researchCompany · Overview
REPH research
Overview
Company profile and research snapshot.
Company profile
Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 12, 2021 | William Blair | Outperform | — |
| May 12, 2020 | Oppenheimer | Outperform | — |
| Mar 5, 2020 | Stephens & Co. | Overweight | — |
| Nov 26, 2019 | Stephens & Co. | Overweight | — |
| Oct 17, 2019 | Stephens & Co. | Overweight | — |
News briefing
No generated briefing is available yet.
GlobeNewswire Inc. · Feb 22, 2022
Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022
Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern
GlobeNewswire Inc. · Jan 26, 2022
Recro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of Topical Treatment for Skin Cancer Prevention
SAN DIEGO, and GAINESVILLE, Ga., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has been awarded a new formulation development and cGMP manufacturing contract from a key department of the United States government. The contract focuses on supporting clinical development of a topical dermal treatment for the prevention of skin cancer.
GlobeNewswire Inc. · Jan 19, 2022
Recro Appoints Eduardo Uribe as Head of Quality for Recro San Diego
Latest Appointment Continues Build-Out of Leadership Team for San Diego Operations Latest Appointment Continues Build-Out of Leadership Team for San Diego Operations
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
